Silence Therapeutics PLC Appointment of Chief Medical Officer (5456U)

TIDMSLN

RNS Number : 5456U

Silence Therapeutics PLC

02 January 2013

Silence Therapeutics plc ("Silence" or the "Company")

Appointment of Chief Medical Officer

Silence Therapeutics plc has appointed Michael Khan its Chief Medical Officer to oversee the company's programme of Phase II clinical trials which are scheduled to start later this year.

Dr Khan became Chief Medical Adviser and a director of the company in September 2012. In his new role he will actively help develop and expand the Silence Therapeutics clinical pipelines in oncology, and acute lung injury, amongst others.

He is an Associate Professor of Medicine at the University of Warwick, a Consultant Physician and Endocrinologist at University Hospitals of Coventry and Warwickshire and Director of the Warwickshire FH and Coronary Prevention Service. He has a strong track record in cancer research and is an editor and co-author of one of the standard textbooks in the field, the Molecular Biology of Cancer.

In recognition of his new commitment, the company will pay an increased consultancy.

Mike said: "These are very exciting times for Silence Therapeutics, with one oncology drug advancing to Phase II. Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise".

Ali Mortazavi, director of Corporate Strategy said: 'I'm delighted Mike has decided to devote more time to us. Next year will be pivotal for Silence after so many years spent preparing for Phase II trials.'

 
 Silence Therapeutics 
  Ali Mortazavi +44 7768 694739 
  a.mortazavi@silence-therapeutics.com 
  Tim Freeborn +44 20 7491 6520 
  t.freeborn@silence-therapeutics.com 
-------------------------------------- 
 N+1 Singer 
  Shaun Dobson/Jenny Wyllie 
  +44 20 7496 3000 
  shaun.dobson@n1singer.com 
  jenny.wyllie@n1singer.com 
--------------------------------------

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBGBDDBDXBGDB

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Oct 2024 to Nov 2024